The US market is unlikely to generate meaningful earnings for infant formula marketer A2 Milk, say analysts at Forsyth Barr, despite the extension of a government programme allowing special market access.
A2 Milk said in November last year it had won approval from the US Food & Drug Administration
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
